New drug combo shows promise for rare bone marrow failure

NCT ID NCT00471848

First seen May 13, 2026 · Last updated May 15, 2026 · Updated 1 time

Summary

This study tested a combination of rabbit antithymocyte globulin (ATG) and ciclosporin in 35 people with acquired aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal was to see if this treatment could improve blood counts and reduce the need for transfusions. Participants received the drugs as their first treatment, and their responses were compared to historical patients who received a horse-derived ATG instead.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Henri Mondor Hospital

    Créteil, France

  • Hopital St. Louis

    Paris, 75475, France

  • King Faisal Specialist Hospital & Research Cnetre

    Riyadh, Saudi Arabia

  • King's College Hospital

    London, United Kingdom

  • Medical University Hannover

    Hanover, Germany

  • Nottingham Universitry Hospital Trust

    Nottingham, United Kingdom

  • Ospedale San Martino

    Genova, 16132, Italy

  • Royal Bournemouth

    Bournemouth, United Kingdom

  • St George's Hospital/ St George's University of London

    London, Sw17 0RE, United Kingdom

  • University Hospital

    Basel, 4031, Switzerland

  • University Hospital Eppendorf

    Hamburg, Germany

  • University Hospital Essen

    Essen, Germany

  • Universitätsklinikum - Institut für klinische Transfusionsmedizin

    Ulm, 89081, Germany

Conditions

Explore the condition pages connected to this study.